<DOC>
	<DOCNO>NCT02059057</DOCNO>
	<brief_summary>Crossover study patient randomize Control Group CLN0009 .</brief_summary>
	<brief_title>LVRC IDE Crossover Study ( Crossover From IDE Trial CLN0009 )</brief_title>
	<detailed_description>Provide LVRC procedure qualify subject enrol Control Subjects complete Lung Volume Reduction Coil Treatment Patients Emphysema ( RENEW ) Study , CLN0009 , obtain safety effectiveness data patient .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>1 . Subject enrol Control Subject complete require study assessment 12 month visit Lung Volume Reduction Coil Treatment Patients Emphysema ( RENEW ) Study , CLN0009 . 2 . Subject postbronchodilator FEV1 ≤45 % predict . 3 . Subject residual volume ( RV ) ≥175 % predict . 4 . Subject stop smoke least 8 week prior enter study , confirm Cotinine test appropriate diagnostic test . 5 . Subject read , understood sign Informed Consent form . 6 . Subject receive Pneumococcal Influenza vaccination consistent local recommendation and/or policy . 1 . Subject severe homogeneous emphysema determine Core Radiology Lab 2 . Subject comorbidities may significantly reduce subject 's ability improve exercise capacity ( e.g . severe arthritis , plan knee surgery ) baseline limitation 6MWT due dyspnea . 3 . Subject change FEV1 &gt; 20 % ( , subject prebronchodilator FEV1 1 L , change &gt; 200 mL ) postbronchodilator , unless investigator confirm mean subject asthma . 4 . Subject DLCO &lt; 20 % predict . 5 . Subject severe gas exchange abnormality define : PaCO2 &gt; 55 mm Hg PaO2 &lt; 45 mm Hg room air ( High altitude criterion : PaO2 &lt; 30 mm Hg ) 6 . Subject history recurrent clinically significant respiratory infection , define 3 hospitalization respiratory infection year prior enrollment . 7 . Subject severe pulmonary hypertension . If pulmonary hypertension present , `` severe '' define right ventricular systolic pressure &gt; 50 mm Hg via right heart catheterization and/or echocardiogram . 8 . Subject inability walk &gt; 140 meter ( 150 yard ) 6 minute . 9 . Subject evidence severe disease ( , limit , lung cancer renal failure ) , judgment investigator may compromise survival subject duration study . 10 . Subject pregnant lactating , plan become pregnant within study timeframe . 11 . Subject inability tolerate bronchoscopy moderate sedation general anesthesia . 12 . Subject clinically significant bronchiectasis . 13 . Subject giant bulla &gt; 1/3 lung volume . 14 . Subject previous LVR surgery , lung transplantation , lobectomy , LVR device device treat COPD either lung . 15 . Subject involved pulmonary drug device study within 30 day prior study , exception RENEW Study . 16 . Subject take &gt; 20 mg prednisone ( equivalent dose similar steroid ) daily . 17 . Subject require high level chronic immunomodulatory therapy treat moderate severe chronic inflammatory autoimmune disorder . 18 . Subject antiplatelet agent ( Plavix ) anticoagulant therapy ( heparin Coumadin ) stop seven ( 7 ) day prior procedure . 19 . Subject sensitivity allergy nitinol ( nickeltitanium ) constituent metal . 20 . Subject know sensitivity drug require perform bronchoscopy . 21 . Subject diagnose alpha1 antitrypsin deficiency ( AATD ) . 22 . Subject disease , condition ( ) habit ( ) would interfere completion study follow assessment , would increase risk bronchoscopy assessment , judgment investigator would potentially interfere compliance study would adversely affect study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>